Global multi-stakeholder endorsement of the MAFLD definition

Nahum Méndez-Sánchez; Elisabetta Bugianesi; Robert G. Gish; Frank Lammert; Herbert Tilg; Mindie H. Nguyen; Shiv K. Sarin; Núria Fabrellas; Shira Zelber-Sagi; Jian Gao Fan; Gamal Shiha; Giovanni Targher; Ming Hua Zheng; Wah Kheong Chan; Shlomo Vinker; Takumi Kawaguchi; Laurent Castéra; Yusuf Yilmaz; Marko Korenjak; C. Wendy Spearman; Mehmet Ungan; Melissa Palmer; Mortada El-Shabrawi; Hans Juergen Gruss; Jean François Dufour; Anil Dhawan; Heiner Wedemeyer; Jacob George; Luca Valenti; Yasser Fouad; Manuel Romero‐Gomez; Mohammed Eslam; the Global multi-stakeholder consensus on the redefinition of fatty liver disease

doi:10.1016/S2468-1253(22)00062-0

Global multi-stakeholder endorsement of the MAFLD definition

Nahum Méndez-Sánchez, Elisabetta Bugianesi, Robert G. Gish, Frank Lammert, Herbert Tilg, Mindie H. Nguyen, Shiv K. Sarin, Núria Fabrellas, Shira Zelber-Sagi, Jian Gao Fan, Gamal Shiha, Giovanni Targher, Ming Hua Zheng, Wah Kheong Chan, Shlomo Vinker, Takumi Kawaguchi, Laurent Castéra, Yusuf Yilmaz, Marko Korenjak, C. Wendy SpearmanMehmet Ungan, Melissa Palmer, Mortada El-Shabrawi, Hans Juergen Gruss, Jean François Dufour, Anil Dhawan, Heiner Wedemeyer, Jacob George, Luca Valenti, Yasser Fouad, Manuel Romero‐Gomez, Mohammed Eslam, the Global multi-stakeholder consensus on the redefinition of fatty liver disease

Research output: Contribution to journal › Letter › Other › peer-review

177 Citations (Scopus)

Original language	English
Pages (from-to)	388-390
Number of pages	3
Journal	The Lancet Gastroenterology & Hepatology
Volume	7
Issue number	5
DOIs	https://doi.org/10.1016/S2468-1253(22)00062-0
Publication status	Published - May 2022

Access to Document

10.1016/S2468-1253(22)00062-0

Cite this

Méndez-Sánchez, N., Bugianesi, E., Gish, R. G., Lammert, F., Tilg, H., Nguyen, M. H., Sarin, S. K., Fabrellas, N., Zelber-Sagi, S., Fan, J. G., Shiha, G., Targher, G., Zheng, M. H., Chan, W. K., Vinker, S., Kawaguchi, T., Castéra, L., Yilmaz, Y., Korenjak, M., ... the Global multi-stakeholder consensus on the redefinition of fatty liver disease (2022). Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology & Hepatology, 7(5), 388-390. https://doi.org/10.1016/S2468-1253(22)00062-0

@article{72611e649cb34007b1457dd78e60e2d3,

title = "Global multi-stakeholder endorsement of the MAFLD definition",

author = "Nahum M{\'e}ndez-S{\'a}nchez and Elisabetta Bugianesi and Gish, {Robert G.} and Frank Lammert and Herbert Tilg and Nguyen, {Mindie H.} and Sarin, {Shiv K.} and N{\'u}ria Fabrellas and Shira Zelber-Sagi and Fan, {Jian Gao} and Gamal Shiha and Giovanni Targher and Zheng, {Ming Hua} and Chan, {Wah Kheong} and Shlomo Vinker and Takumi Kawaguchi and Laurent Cast{\'e}ra and Yusuf Yilmaz and Marko Korenjak and Spearman, {C. Wendy} and Mehmet Ungan and Melissa Palmer and Mortada El-Shabrawi and Gruss, {Hans Juergen} and Dufour, {Jean Fran{\c c}ois} and Anil Dhawan and Heiner Wedemeyer and Jacob George and Luca Valenti and Yasser Fouad and Manuel Romero‐Gomez and Mohammed Eslam and Abate, {Maria Lorena} and Bahaa Abbas and Abbassy, {Ahmed Amr} and {Abd El Ghany}, Waleed and {Abd Elkhalek}, Amira and {Abd ElMajeed}, Emad and Mohammad Abdalgaber and Mohamed AbdAllah and Marwa Abdallah and Nourhan Abdallah and Shereen Abdelaleem and Yasser Abdelghani and Wael Abdelghany and Abdelhalim, {Safaa Mohamed} and Wafaa Abdelhamid and Nehal Abdelhamid and Abdelkader, {Nadia A.} and Elsayed Abdelkreem and Abdelmohsen, {Aly Mohamed} and Abdelrahman, {Awny Ali} and Abd-elsalam, {Sherief M.} and Doaa Abdeltawab and Abdulbaset Abduh and Nada Abdulhakam and Maheeba Abdulla and Navid Abedpoor and Ludovico Abenavoli and Fredrik {\AA}berg and Omala Ablack and {Abo elftouh}, Mostafa and Abo-Amer, {Yousry Esam Eldin} and Ashraf Aboubkr and Alaa Aboud and Abouelnaga, {Amr M.} and Aboufarrag, {Galal A.} and Ashraf Aboutaleb and Leticia Abundis and Gupse Adalı and Enrique Adames and Leon Adams and Danjuma Adda and Noor Adel and Nada Adel and {Adel Sayed}, Muhammad and Afaa, {Taiba Jibril} and Nawal Afredj and Gulnara Aghayeva and Alessio Aghemo and Aguilar-Salinas, {Carlos A.} and Golo Ahlenstiel and Walid Ahmady and Wafaa Ahmed and Amira Ahmed and Ahmed, {Samah Nasser} and Ahmed, {Heba Mostafa} and Rasha Ahmed and Elmar Aigner and Mesut Akarsu and Maisam Akroush and Umit Akyuz and {Al Mahtab}, Mamun and {Al Qadiri}, Tahani and {Al Rawahi}, Yusriya and {AL rubaee}, Razzaq and {Al Saffar}, Muna and Shahinul Alam and Zaid Al-Ani and Agust{\'i}n Albillos and Mohamed Alboraie and Said Al-Busafi and Mohamed Al-Emam and Jawaher Alharthi and Kareem Ali and Ali, {Basma Abdelmoez} and Mohammad Ali and Ali, {Raja Affendi Raja} and Anna Alisi and AL-Khafaji, {Ali Raad} and Maryam Alkhatry and Rocio Aller and Yahya Almansoury and Khalid Al-Naamani and Alaa Alnakeeb and Anna Alonso and Alqahtani, {Saleh A.} and Leina Alrabadi and Khalid Alswat and Mahir Altaher and Turki Altamimi and Jose Altamirano and Alvares-da-Silva, {Mario R.} and Aly, {Elsragy Adel M.} and Amgad Alzahaby and Ahmed Alzamzamy and Keisuke Amano and Amer, {Maysa A.} and Amin, {Mona A.} and Amin, {Sayed A.} and Amir, {Ashraf A.} and Javier Ampuero and Noha Anas and Pietro Andreone and Andriamandimby, {Soa Fy} and Mahmoud Anees and Peltec Angela and Manal Antonios and Wael Arafat and Araya, {Jose Moreno} and Juan Armendariz-Borunda and Armstrong, {Matthew J.} and Hassan Ashktorab and Patricia Aspichueta and Fathia Assal and Mira Atef and Dina Attia and Hoda Atwa and Reham Awad and Awad, {Mohyeldeen Abd Elaziz} and Sally Awny and Obafemi Awolowo and Awuku, {Yaw Asante} and Ibrahim Ayada and Aye, {Than Than} and Sherif Ayman and Hedy Ayman and Hesham Ayoub and Azmy, {Hosny M.} and Babaran, {Romiro P.} and Omneya Badreldin and Ahmed Badry and Bah{\c c}ecioğlu, {İbrahim Halil} and Amira Bahour and Jiajia Bai and Yasemin Balaban and Muthuswamy Balasubramanyam and Khaled Bamakhrama and Banales, {Jesus M.} and Babu Bangaru and Jianfeng Bao and Barahona, {Jorge Suazo} and Salma Barakat and Barbalho, {Sandra Maria} and Bikwa Barbra and Beatriz Barranco and Francisco Barrera and Ulrich Baumann and Shamardan Bazeed and Eva Bech and Aourarh Benayad and Andreas Benesic and David Bernstein and Fernando Bessone and Susie Birney and Cyrille Bisseye and Martin Blake and Bilal Bobat and Leonilde Bonfrate and Bordin, {Dmitry S.} and Francisco Bosques-Padilla and Jerome Boursier and Boushab, {Boushab Mohamed} and David Bowen and Bravo, {Patricia Medina} and Brennan, {Paul N.} and Bisi Bright and Ilse Broekaert and Xabier Buque and Diego Burgos-Santamar{\'i}a and Julio Burman and Luca Busetto and Byrne, {Chris D.} and Cabral-Prodigalidad, {Patricia Anne I.} and Guillermo Cabrera-Alvarez and Wei Cai and Francesca Cainelli and Caliskan, {Ali Riza} and Ali Canbay and Ana Cano-Contreras and Cao, {Hai Xia} and Zhujun Cao and Andres Carrion and Francesca Carubbi and Teresa Casanovas and {Castellanos Fern{\'a}ndez}, {Marlen Iv{\'o}n} and Jin Chai and Chan, {Siew Pheng} and Phunchai Charatcharoenwitthaya and Norberto Chavez-Tapia and Kazuaki Chayama and Jinjun Chen and Lin Chen and Chen, {Zhong Wei} and Huiting Chen and Chen, {Sui Dan} and Qiang Chen and Yaxi Chen and Gang Chen and Chen, {En Quang} and Fei Chen and Chen, {Pei Jer} and Robert Cheng and Wendy Cheng and Chieh, {Jack Tan Wei} and Imad Chokr and Evangelos Cholongitas and Ashok Choudhury and Abhijit Chowdhury and Chukwudike, {Evaristus Sunday} and Stefano Ciardullo and Anouk Dev and James Haridy and Alexander Hodge and John Lubel and Ammar Majeed and Amanda Nicoll and Stuart Roberts and Rohit Sawhney and William Sievert and {the Global multi-stakeholder consensus on the redefinition of fatty liver disease}",

note = "Funding Information: HW reports personal fees from Falk Foundation, Gore, Intercept, Pfizer, Merz, and Norgine; and grants from Merz and from Norgine, unrelated to this Correspondence. W-KC reports personal fees from Abbvie, Novo Nordisk, Boehringer Ingelheim, Viatris, and Hisky Medical, unrelated to this Correspondence. TK reports honorarium for lectures from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, and EA Pharma, unrelated to this Correspondence. LC reports personal fees from Alexion, AbbVie, Echosens, Gilead, Intercept, Merck, Novo Nordisk, and Pfizer; and grants from Gilead, unrelated to this Correspondence. MHN reports grants from Glycotest, Gilead, Pfizer, Enanta, BK Kee Foundation, National Cancer Institute, and Vir Biotech; and personal fees from Spring Bank, Novartis, Janssen Eisai, Bayer, Intercept, Exact Science, Laboratory of Advanced Medicine, Helio, and Eli Lilly. MHN also reports acting as a consultant or on an advisory board for Gilead, unrelated to this Correspondence. LV reports grants from Gilead and personal fees from Viatris, unrelated to this Correspondence. RGG has received grants or research support in past 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG has performed as a consultant, advisor, or both to Topography Health. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm–Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, ArrowHead, Arterys, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Association, CymaBay Therapeutics, DiaSorin, Dova Pharmaceuticals, DRG Abacus, Durect, Dynavax, Echosens, Eiger, Enyp, Exelixis, Fibronostics, Forty-Seven, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen–Johnson & Johnson, KannaLife, Laboratory for Advanced Medicine, Labyrinth, Life Line Screening, Eli Lilly, MedImmne, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, and Trimaran. RGG has speaker's contracts to do promotional talks for AbbVie, Bristol Myers Squibb, Eisai, Gilead Sciences, and Intercept. RGG is a minor stock shareholder (only for projects in the liver field but not fatty liver disease-related areas) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, and AngioCrine, unrelated to this Correspondence. All other authors declare no competing interests. ",

year = "2022",

month = may,

doi = "10.1016/S2468-1253(22)00062-0",

language = "English",

volume = "7",

pages = "388--390",

journal = "The Lancet Gastroenterology & Hepatology",

issn = "2468-1253",

publisher = "Elsevier",

number = "5",

}

Méndez-Sánchez, N, Bugianesi, E, Gish, RG, Lammert, F, Tilg, H, Nguyen, MH, Sarin, SK, Fabrellas, N, Zelber-Sagi, S, Fan, JG, Shiha, G, Targher, G, Zheng, MH, Chan, WK, Vinker, S, Kawaguchi, T, Castéra, L, Yilmaz, Y, Korenjak, M, Spearman, CW, Ungan, M, Palmer, M, El-Shabrawi, M, Gruss, HJ, Dufour, JF, Dhawan, A, Wedemeyer, H, George, J, Valenti, L, Fouad, Y, Romero‐Gomez, M, Eslam, M & the Global multi-stakeholder consensus on the redefinition of fatty liver disease 2022, 'Global multi-stakeholder endorsement of the MAFLD definition', The Lancet Gastroenterology & Hepatology, vol. 7, no. 5, pp. 388-390. https://doi.org/10.1016/S2468-1253(22)00062-0

TY - JOUR

T1 - Global multi-stakeholder endorsement of the MAFLD definition

AU - Méndez-Sánchez, Nahum

AU - Bugianesi, Elisabetta

AU - Gish, Robert G.

AU - Lammert, Frank

AU - Tilg, Herbert

AU - Nguyen, Mindie H.

AU - Sarin, Shiv K.

AU - Fabrellas, Núria

AU - Zelber-Sagi, Shira

AU - Fan, Jian Gao

AU - Shiha, Gamal

AU - Targher, Giovanni

AU - Zheng, Ming Hua

AU - Chan, Wah Kheong

AU - Vinker, Shlomo

AU - Kawaguchi, Takumi

AU - Castéra, Laurent

AU - Yilmaz, Yusuf

AU - Korenjak, Marko

AU - Spearman, C. Wendy

AU - Ungan, Mehmet

AU - Palmer, Melissa

AU - El-Shabrawi, Mortada

AU - Gruss, Hans Juergen

AU - Dufour, Jean François

AU - Dhawan, Anil

AU - Wedemeyer, Heiner

AU - George, Jacob

AU - Valenti, Luca

AU - Fouad, Yasser

AU - Romero‐Gomez, Manuel

AU - Eslam, Mohammed

AU - Abate, Maria Lorena

AU - Abbas, Bahaa

AU - Abbassy, Ahmed Amr

AU - Abd El Ghany, Waleed

AU - Abd Elkhalek, Amira

AU - Abd ElMajeed, Emad

AU - Abdalgaber, Mohammad

AU - AbdAllah, Mohamed

AU - Abdallah, Marwa

AU - Abdallah, Nourhan

AU - Abdelaleem, Shereen

AU - Abdelghani, Yasser

AU - Abdelghany, Wael

AU - Abdelhalim, Safaa Mohamed

AU - Abdelhamid, Wafaa

AU - Abdelhamid, Nehal

AU - Abdelkader, Nadia A.

AU - Abdelkreem, Elsayed

AU - Abdelmohsen, Aly Mohamed

AU - Abdelrahman, Awny Ali

AU - Abd-elsalam, Sherief M.

AU - Abdeltawab, Doaa

AU - Abduh, Abdulbaset

AU - Abdulhakam, Nada

AU - Abdulla, Maheeba

AU - Abedpoor, Navid

AU - Abenavoli, Ludovico

AU - Åberg, Fredrik

AU - Ablack, Omala

AU - Abo elftouh, Mostafa

AU - Abo-Amer, Yousry Esam Eldin

AU - Aboubkr, Ashraf

AU - Aboud, Alaa

AU - Abouelnaga, Amr M.

AU - Aboufarrag, Galal A.

AU - Aboutaleb, Ashraf

AU - Abundis, Leticia

AU - Adalı, Gupse

AU - Adames, Enrique

AU - Adams, Leon

AU - Adda, Danjuma

AU - Adel, Noor

AU - Adel, Nada

AU - Adel Sayed, Muhammad

AU - Afaa, Taiba Jibril

AU - Afredj, Nawal

AU - Aghayeva, Gulnara

AU - Aghemo, Alessio

AU - Aguilar-Salinas, Carlos A.

AU - Ahlenstiel, Golo

AU - Ahmady, Walid

AU - Ahmed, Wafaa

AU - Ahmed, Amira

AU - Ahmed, Samah Nasser

AU - Ahmed, Heba Mostafa

AU - Ahmed, Rasha

AU - Aigner, Elmar

AU - Akarsu, Mesut

AU - Akroush, Maisam

AU - Akyuz, Umit

AU - Al Mahtab, Mamun

AU - Al Qadiri, Tahani

AU - Al Rawahi, Yusriya

AU - AL rubaee, Razzaq

AU - Al Saffar, Muna

AU - Alam, Shahinul

AU - Al-Ani, Zaid

AU - Albillos, Agustín

AU - Alboraie, Mohamed

AU - Al-Busafi, Said

AU - Al-Emam, Mohamed

AU - Alharthi, Jawaher

AU - Ali, Kareem

AU - Ali, Basma Abdelmoez

AU - Ali, Mohammad

AU - Ali, Raja Affendi Raja

AU - Alisi, Anna

AU - AL-Khafaji, Ali Raad

AU - Alkhatry, Maryam

AU - Aller, Rocio

AU - Almansoury, Yahya

AU - Al-Naamani, Khalid

AU - Alnakeeb, Alaa

AU - Alonso, Anna

AU - Alqahtani, Saleh A.

AU - Alrabadi, Leina

AU - Alswat, Khalid

AU - Altaher, Mahir

AU - Altamimi, Turki

AU - Altamirano, Jose

AU - Alvares-da-Silva, Mario R.

AU - Aly, Elsragy Adel M.

AU - Alzahaby, Amgad

AU - Alzamzamy, Ahmed

AU - Amano, Keisuke

AU - Amer, Maysa A.

AU - Amin, Mona A.

AU - Amin, Sayed A.

AU - Amir, Ashraf A.

AU - Ampuero, Javier

AU - Anas, Noha

AU - Andreone, Pietro

AU - Andriamandimby, Soa Fy

AU - Anees, Mahmoud

AU - Angela, Peltec

AU - Antonios, Manal

AU - Arafat, Wael

AU - Araya, Jose Moreno

AU - Armendariz-Borunda, Juan

AU - Armstrong, Matthew J.

AU - Ashktorab, Hassan

AU - Aspichueta, Patricia

AU - Assal, Fathia

AU - Atef, Mira

AU - Attia, Dina

AU - Atwa, Hoda

AU - Awad, Reham

AU - Awad, Mohyeldeen Abd Elaziz

AU - Awny, Sally

AU - Awolowo, Obafemi

AU - Awuku, Yaw Asante

AU - Ayada, Ibrahim

AU - Aye, Than Than

AU - Ayman, Sherif

AU - Ayman, Hedy

AU - Ayoub, Hesham

AU - Azmy, Hosny M.

AU - Babaran, Romiro P.

AU - Badreldin, Omneya

AU - Badry, Ahmed

AU - Bahçecioğlu, İbrahim Halil

AU - Bahour, Amira

AU - Bai, Jiajia

AU - Balaban, Yasemin

AU - Balasubramanyam, Muthuswamy

AU - Bamakhrama, Khaled

AU - Banales, Jesus M.

AU - Bangaru, Babu

AU - Bao, Jianfeng

AU - Barahona, Jorge Suazo

AU - Barakat, Salma

AU - Barbalho, Sandra Maria

AU - Barbra, Bikwa

AU - Barranco, Beatriz

AU - Barrera, Francisco

AU - Baumann, Ulrich

AU - Bazeed, Shamardan

AU - Bech, Eva

AU - Benayad, Aourarh

AU - Benesic, Andreas

AU - Bernstein, David

AU - Bessone, Fernando

AU - Birney, Susie

AU - Bisseye, Cyrille

AU - Blake, Martin

AU - Bobat, Bilal

AU - Bonfrate, Leonilde

AU - Bordin, Dmitry S.

AU - Bosques-Padilla, Francisco

AU - Boursier, Jerome

AU - Boushab, Boushab Mohamed

AU - Bowen, David

AU - Bravo, Patricia Medina

AU - Brennan, Paul N.

AU - Bright, Bisi

AU - Broekaert, Ilse

AU - Buque, Xabier

AU - Burgos-Santamaría, Diego

AU - Burman, Julio

AU - Busetto, Luca

AU - Byrne, Chris D.

AU - Cabral-Prodigalidad, Patricia Anne I.

AU - Cabrera-Alvarez, Guillermo

AU - Cai, Wei

AU - Cainelli, Francesca

AU - Caliskan, Ali Riza

AU - Canbay, Ali

AU - Cano-Contreras, Ana

AU - Cao, Hai Xia

AU - Cao, Zhujun

AU - Carrion, Andres

AU - Carubbi, Francesca

AU - Casanovas, Teresa

AU - Castellanos Fernández, Marlen Ivón

AU - Chai, Jin

AU - Chan, Siew Pheng

AU - Charatcharoenwitthaya, Phunchai

AU - Chavez-Tapia, Norberto

AU - Chayama, Kazuaki

AU - Chen, Jinjun

AU - Chen, Lin

AU - Chen, Zhong Wei

AU - Chen, Huiting

AU - Chen, Sui Dan

AU - Chen, Qiang

AU - Chen, Yaxi

AU - Chen, Gang

AU - Chen, En Quang

AU - Chen, Fei

AU - Chen, Pei Jer

AU - Cheng, Robert

AU - Cheng, Wendy

AU - Chieh, Jack Tan Wei

AU - Chokr, Imad

AU - Cholongitas, Evangelos

AU - Choudhury, Ashok

AU - Chowdhury, Abhijit

AU - Chukwudike, Evaristus Sunday

AU - Ciardullo, Stefano

AU - Dev, Anouk

AU - Haridy, James

AU - Hodge, Alexander

AU - Lubel, John

AU - Majeed, Ammar

AU - Nicoll, Amanda

AU - Roberts, Stuart

AU - Sawhney, Rohit

AU - Sievert, William

AU - the Global multi-stakeholder consensus on the redefinition of fatty liver disease

N1 - Funding Information: HW reports personal fees from Falk Foundation, Gore, Intercept, Pfizer, Merz, and Norgine; and grants from Merz and from Norgine, unrelated to this Correspondence. W-KC reports personal fees from Abbvie, Novo Nordisk, Boehringer Ingelheim, Viatris, and Hisky Medical, unrelated to this Correspondence. TK reports honorarium for lectures from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, and EA Pharma, unrelated to this Correspondence. LC reports personal fees from Alexion, AbbVie, Echosens, Gilead, Intercept, Merck, Novo Nordisk, and Pfizer; and grants from Gilead, unrelated to this Correspondence. MHN reports grants from Glycotest, Gilead, Pfizer, Enanta, BK Kee Foundation, National Cancer Institute, and Vir Biotech; and personal fees from Spring Bank, Novartis, Janssen Eisai, Bayer, Intercept, Exact Science, Laboratory of Advanced Medicine, Helio, and Eli Lilly. MHN also reports acting as a consultant or on an advisory board for Gilead, unrelated to this Correspondence. LV reports grants from Gilead and personal fees from Viatris, unrelated to this Correspondence. RGG has received grants or research support in past 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG has performed as a consultant, advisor, or both to Topography Health. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm–Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, ArrowHead, Arterys, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Association, CymaBay Therapeutics, DiaSorin, Dova Pharmaceuticals, DRG Abacus, Durect, Dynavax, Echosens, Eiger, Enyp, Exelixis, Fibronostics, Forty-Seven, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen–Johnson & Johnson, KannaLife, Laboratory for Advanced Medicine, Labyrinth, Life Line Screening, Eli Lilly, MedImmne, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, and Trimaran. RGG has speaker's contracts to do promotional talks for AbbVie, Bristol Myers Squibb, Eisai, Gilead Sciences, and Intercept. RGG is a minor stock shareholder (only for projects in the liver field but not fatty liver disease-related areas) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, and AngioCrine, unrelated to this Correspondence. All other authors declare no competing interests.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85127533180&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(22)00062-0

DO - 10.1016/S2468-1253(22)00062-0

M3 - Letter

C2 - 35248211

AN - SCOPUS:85127533180

SN - 2468-1253

VL - 7

SP - 388

EP - 390

JO - The Lancet Gastroenterology & Hepatology

JF - The Lancet Gastroenterology & Hepatology

IS - 5

ER -

Global multi-stakeholder endorsement of the MAFLD definition

Access to Document

Other files and links

Cite this